Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas
Jakub Svoboda,
Steven M. Bair,
Daniel J. Landsburg,
Sunita Dwivedy Nasta,
Sarah J. Nagle,
Stefan K. Barta,
Nadia Khan,
Joanne Filicko-O'Hara,
Sameh Gaballa,
Lauren Strelec,
Elise Chong,
Sheryl Mitnick,
Terease S. Waite,
Cara King,
Hatcher Ballard,
Matthew Youngman,
James Gerson,
John P. Plastaras,
Amit Maity,
Agata M. Bogusz,
Stacy S. Hung,
Hisae Nakamura,
Reza Nejati,
Christian Steidl,
Megan Lim,
Marco Ruella,
Stephen J. Schuster
Affiliations
Jakub Svoboda
University of Pennsylvania, Philadelphia, PA, USA;
Steven M. Bair
University of Pennsylvania, Philadelphia, PA, USA;
Daniel J. Landsburg
University of Pennsylvania, Philadelphia, PA, USA;
Sunita Dwivedy Nasta
University of Pennsylvania, Philadelphia, PA, USA;
Sarah J. Nagle
Oregon Health and Science University, Portland, OR, USA;
Stefan K. Barta
University of Pennsylvania, Philadelphia, PA, USA;
Nadia Khan
Fox Chase Cancer Center, Philadelphia, PA, USA;
Joanne Filicko-O'Hara
Thomas Jefferson University, Philadelphia, PA, USA;
Sameh Gaballa
Thomas Jefferson University, Philadelphia, PA, USA;
Lauren Strelec
University of Pennsylvania, Philadelphia, PA, USA;
Elise Chong
University of Pennsylvania, Philadelphia, PA, USA;
Sheryl Mitnick
University of Pennsylvania, Philadelphia, PA, USA;
Terease S. Waite
University of Pennsylvania, Philadelphia, PA, USA;
Cara King
University of Pennsylvania, Philadelphia, PA, USA;
Hatcher Ballard
University of Pennsylvania, Philadelphia, PA, USA;
Matthew Youngman
University of Pennsylvania, Philadelphia, PA, USA;
James Gerson
University of Pennsylvania, Philadelphia, PA, USA;
John P. Plastaras
University of Pennsylvania, Philadelphia, PA, USA;
Amit Maity
University of Pennsylvania, Philadelphia, PA, USA;
Agata M. Bogusz
University of Pennsylvania, Philadelphia, PA, USA;
Stacy S. Hung
Centre for Lymphoid Cancer, Vancouver, BC, Canada
Hisae Nakamura
Centre for Lymphoid Cancer, Vancouver, BC, Canada
Reza Nejati
Fox Chase Cancer Center, Philadelphia, PA, USA;
Christian Steidl
Centre for Lymphoid Cancer, Vancouver, BC, Canada
Megan Lim
University of Pennsylvania, Philadelphia, PA, USA;
Marco Ruella
University of Pennsylvania, Philadelphia, PA, USA;
Stephen J. Schuster
University of Pennsylvania, Philadelphia, PA, USA;
We conducted a phase I/II multicenter trial using 6 cycles of brentuximab vedotin (BV) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for treatment of patients with CD30-positive (+) B-cell lymphomas. Thirty-one patients were evaluable for toxicity and 29 for efficacy including 22 with primary mediastinal B-cell lymphoma (PMBCL), 5 with diffuse large B-cell lymphoma (DLBCL), and 2 with gray zone lymphoma (GZL). There were no treatment-related deaths; 32% of patients had non-hematological grade 3/4 toxicities. The overall response rate was 100% (95% CI: 88-100) with 86% (95% CI: 68-96) of patients achieving complete response at the end of systemic treatment. Consolidative radiation following end of treatment response assessment was permissible and used in 52% of all patients including 59% of patients with PMBCL. With a median follow-up of 30 months, the 2-year progression-free survival (PFS) and overall survival (OS) were 85% (95% CI: 66-94) and 100%, respectively. In the PMBCL cohort, 2-year PFS was 86% (95% CI: 62-95). In summary, BV-R-CHP with or without consolidative radiation is a feasible and active frontline regimen for CD30+ B-cell lymphomas (NCT01994850).
